SGLT2-IN-2

• Description:

  SGLT2-IN-2 (Compound E9) is an inhibitor of SGLT2. SGLT2-IN-2 significantly enhances the inhibition of SGLT2, NHE1, and SOD enzyme activity. SGLT2-IN-2 has protective effect on the glucose-free DMEM-induced injured cardiomyocytes. SGLT2-IN-2 significantly improves cardiac function in TAC-induced HF mice and inhibits cardiomyocyte hypertrophy as well as collagen deposition. SGLT2-IN-2 can ameliorate myocardial tissue damage and enhance mitochondrial autophagy in injured cardiomyocytes, thereby increasing survival rates in HF mice[1].

• UNSPSC:

  12352005

• Target:

  Autophagy; Na+/H+ Exchanger (NHE) ; SGLT; SOD

• Related Pathways:

  Autophagy; Immunology/Inflammation; Membrane Transporter/Ion Channel

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Purity:

  99.57

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O[C@@H]1[C@@H](CO)O[C@@H](OC2=CC=C(C3=CN(CC4=CC=CN=C4)N=C3C)C=C2)[C@H](O)[C@H]1O

• Molecular Formula:

  C22H25N3O6

• Molecular Weight:

  427.45

• References & Citations:

  [1]Liu, Y., et al., (2025) . Design, synthesis and evaluation of anti-heart failure activity of O-glucoside derivatives. European journal of medicinal chemistry, 296, 117802.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported